Sandoz’s Tyruko first MS biosimilar launched in USA

Swiss generics and biosimilars company Sandoz (SIX:SDZ) has announced the launch of Tyruko (natalizumab-sztn) in the USA.

Developed by fellow Swiss firm Polpharma Biologics, Tyruko is the first and only US Food and Drug Administration (FDA)-approved biosimilar of Biogen’s (Nasdaq: BIIB) Tysabri (natalizumab) for the treatment of relapsing forms of multiple sclerosis (MS).

Sandoz entered into a global commercialization agreement for biosimilar natalizumab in 2019. Under this agreement, Polpharma will maintain responsibility for the development of the medicine, manufacturing and supply of the drug substance.